BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.
BiomX Inc. (NYSE American: PHGE), un'azienda in fase clinica specializzata in terapie con fagi mirate a batteri patogeni specifici, ha annunciato di aver ricevuto una notifica scritta dalla NYSE American, datata 10 dicembre 2024. La notifica conferma che BiomX ha ripristinato la conformità a tutti gli standard di mantenimento della quotazione NYSE American. Questa conformità rettifica le carenze osservate il 23 maggio 2024, come delineato nelle Sezioni 1003(a)(i), (ii) e (iii) della Guida per le Aziende NYSE American. NYSE American ha verificato che BiomX ha soddisfatto gli standard di mantenimento della quotazione per due trimestri consecutivi, in conformità con la Sezione 1009(f) della Guida per le Aziende.
BiomX Inc. (NYSE American: PHGE), una empresa en fase clínica centrada en terapias con fagos que atacan bacterias patógenas específicas, anunció que ha recibido una notificación por escrito de NYSE American, fechada el 10 de diciembre de 2024. La notificación confirma que BiomX ha recuperado el cumplimiento de todos los estándares de cotización continua de NYSE American. Este cumplimiento rectifica las deficiencias señaladas el 23 de mayo de 2024, tal como se detalla en las Secciones 1003(a)(i), (ii) y (iii) de la Guía para Empresas de NYSE American. NYSE American verificó que BiomX ha cumplido con los estándares de cotización continua durante dos trimestres consecutivos, de acuerdo con la Sección 1009(f) de la Guía para Empresas.
BiomX Inc. (NYSE American: PHGE)는 특정 병원성 세균을 겨냥한 파지 치료에 중점을 두고 있는 임상 단계 회사로, 2024년 12월 10일자 NYSE American에서 받은 서면 통지를 발표했습니다. 이 통지는 BiomX가 NYSE American의 모든 계속 상장 기준을 준수하게 됐음을 확인합니다. 이 준수는 2024년 5월 23일 언급된 결함을 수정하며, NYSE American 기업 가이드의 섹션 1003(a)(i), (ii) 및 (iii)에 명시되어 있습니다. NYSE American은 BiomX가 기업 가이드의 섹션 1009(f)에 따라 두 개의 연속 분기 동안 계속 상장 기준을 충족했음을 확인했습니다.
BiomX Inc. (NYSE American: PHGE), une entreprise en phase clinique axée sur les thérapies par phages ciblant des bactéries pathogènes spécifiques, a annoncé avoir reçu une notification écrite de NYSE American, datée du 10 décembre 2024. La notification confirme que BiomX a retrouvé sa conformité avec tous les critères de maintien de la cotation NYSE American. Cette conformité rectifie les carences notées le 23 mai 2024, comme indiqué dans les sections 1003(a)(i), (ii) et (iii) du guide des entreprises NYSE American. NYSE American a vérifié que BiomX a respecté les critères de maintien de la cotation pendant deux trimestres consécutifs, conformément à la section 1009(f) du guide des entreprises.
BiomX Inc. (NYSE American: PHGE), ein klinisches Unternehmen, das sich auf Phagentherapien zur Bekämpfung spezifischer pathogener Bakterien spezialisiert hat, gab bekannt, dass es am 10. Dezember 2024 eine schriftliche Benachrichtigung von NYSE American erhalten hat. Die Benachrichtigung bestätigt, dass BiomX die Einhaltung aller fortlaufenden Notierungsstandards der NYSE American wiedererlangt hat. Diese Einhaltung behebt die Mängel, die am 23. Mai 2024 festgestellt wurden, wie in den Abschnitten 1003(a)(i), (ii) und (iii) des NYSE American Company Guide aufgeführt. NYSE American hat bestätigt, dass BiomX die fortlaufenden Notierungsstandards zwei aufeinanderfolgende Quartale lang erfüllt hat, gemäß Abschnitt 1009(f) des Unternehmensleitfadens.
- BiomX has regained compliance with all NYSE American continued listing standards.
- The company has resolved prior listing deficiencies noted on May 23, 2024.
- BiomX demonstrated compliance for two consecutive quarters.
- Previous listing deficiencies were noted by NYSE American on May 23, 2024.
NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification from the NYSE American LLC (“NYSE American”), dated December 10, 2024, stating that the Company has regained compliance with all NYSE American LLC continued listing standards. Specifically, the Company has resolved prior listing deficiencies raised on May 23, 2024, by NYSE American and set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”). NYSE American confirmed that the Company has demonstrated compliance with the continued listing standard for a period of two consecutive quarters pursuant to Section 1009(f) of the Company Guide.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Safe Harbor
This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, the Company is making forward-looking statements when it discusses its ability to continue to remain in compliance with NYSE American listing standards. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 4, 2024, and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.
Contacts:
BiomX, Inc.
Ben Cohen
benc@biomx.com
CORE IR
Peter Seltzberg
ir-biomx@biomx.com
FAQ
What does the PHGE compliance with NYSE American listing standards mean for shareholders?
When did BiomX Inc. regain compliance with NYSE American standards?
What were the deficiencies BiomX Inc. had to resolve for NYSE American compliance?
How long did BiomX Inc. demonstrate compliance with NYSE American standards?
What is the significance of BiomX Inc.'s compliance with Section 1009(f) of the Company Guide?
